EUROAPI updates its 2022 financial guidance
Swiss firm Ferring Pharmaceuticals has announced that Propess® (dinoprostone) has been approved by the Minister of Health, Labour and Welfare (MHLW) in Japan for initiation of cervical ripening in patients at term (from 37 completed weeks of gestation). This is the first time in over 20 years that a pharmacological therapy for cervical ripening has been approved in the country.
Enforcement Report - Week of April 24, 2019
Enforcement Report - Week of August 22, 2018
Enforcement Report - Week of January 17, 2018
As part of the agreement, AZ will sell the following brands of Bricarex, Bricarex-A, Bricanyl, Xylocard, Ceriviprime, Prostodin, Partocin and Primiprost in India to Zydus Healthcare, these brands were discontinued by the company in Indian market.
Western Drug recalls Prostin injection due to Lack of Assurance of Sterility
Francis Crick Institute researchers, funded by Cancer Research UK, have shown that skin, breast and bowel cancer cells often produce large amounts of prostaglandin E2 (PGE2). This molecule dampens down the immune system's normal response to attack faulty cells, which helps cancer to hide. It is a trick that allows the tumour to thrive and may explain why some immunotherapy treatments have not been as effective as hoped.